About The Study: In this randomized clinical trial, early treatment with metformin was not superior to placebo for the composite primary outcome of insulin initiation or a fasting glucose level of 5.1 mmol/L or greater at gestation weeks 32 or 38. Prespecified secondary outcome data support further investigation of metformin in larger clinical trials.
Authors: Fidelma Dunne, Ph.D., of the University of Galway in Galway, Ireland, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2023.19869)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Media advisory: This study is being released to coincide with presentation at the European Association for the Study of Diabetes Annual Meeting 2023.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2023.19869?guestAccessKey=8568ea62-6457-41dc-8a4d-c197f621be42&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=100323
Journal
JAMA